- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06103123
MYocarditis en/of pericarditis na mRNA COVID-19 VACCinatie Nationale Surveillancestudie (MYCOVACC)
Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the lining surrounding the heart muscle. Symptoms of these conditions can include pain in the chest and rapid or irregular heartbeat. There are many different causes for myocarditis and pericarditis including COVID-19 infection.
The MYCOVACC study will identify patients using local screening strategies, including research communications, care provider referrals, and medical record review. The retrospective component of the study will collect information about patients suffering from vaccine associated myopericarditis and COVID-19 associated myopericarditis. Consenting patients will then be prospectively followed according to standard of care protocols. The main objectives of MYCOVACC are to describe the rate of major adverse cardiovascular events, functional outcomes including quality of life, and myocardial recovery through imaging.
Studie Overzicht
Toestand
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Jenny Petterson, MSc
- Telefoonnummer: 604-875-5104
- E-mail: jenny.petterson@vch.ca
Studie Contact Back-up
- Naam: Naomi Uchida, RN
- Telefoonnummer: 604-875-5324
- E-mail: naomi-uchida@ubc.ca
Studie Locaties
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Werving
- Vancouver General Hospital
-
Contact:
- Jenny Petterson, MSc
- Telefoonnummer: 604 - 875 - 5104
- E-mail: jenny.petterson@vch.ca
-
Hoofdonderzoeker:
- Nathaniel Hawkins, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients who have suffered or are suffering from 1) COVID-19 infection associated myocarditis, 2) COVID-19 infection associated pericarditis, 3) COVID-19 vaccine associated myocarditis, 4) COVID-19 vaccine associated pericarditis, 5) Alternative etiology myocarditis, 6) Alternative etiology pericarditis
Definition of myocarditis and pericarditis follows standard clinical definition as outlined in "Brighton Collaboration myocarditis case definition and levels of diagnostic certainty 1,2 and 3"
Beschrijving
Inclusion Criteria:
-
Inclusion criteria for vaccine associated myocarditis/pericarditis.
-
COVID-19 vaccination within previous 42 days. AND
-
At least one cardiac symptom of suspected myocarditis/pericarditis (Appendix 5).
OR At least two non-specific symptoms (Appendix 5). OR In infants and young children, at least two non-specific pediatric symptoms (Appendix 5).
OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI).
AND
-
At least one of the following objective findings (Brighton Criteria case definitions, Appendices 1 to 5):
- Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation.
- Elevated myocardial biomarker (Troponin T, Troponin I, or CK-MB).
- Cardiac MRI abnormality.
- Echocardiographic abnormality.
- New or worsening arrhythmia on electrocardiogram, Holter monitor, or telemetry.
- Elevated inflammation biomarkers: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hs-CRP, or D-Dimer.
- Physical examination pericardial friction rub or pulsus paradoxus.
- Pericardial fluid or inflammation by imaging (echo, MRI, or CT).
- Enlarged heart on chest radiograph.
AND
-
No alternative cause of presentation. e.g. infectious or autoimmune myocarditis.
-
-
Inclusion criteria for COVID-19 associated myocarditis/pericarditis
-
COVID-19 infection within the previous 42 days.
AND
-
Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis.
AND
-
No alternative cause of presentation.
-
Inclusion criteria alternative etiology myocarditis.
-
Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis.
AND
-
No alternative cause of presentation.
Exclusion Criteria:
- For prospective invitation and follow-up, inability to provide informed consent. Consent will be sought from patients or their authorised substitute decision maker.
- Patients not fulfilling Brighton Criteria levels 1-3 will be excluded if they are level 4 (insufficient evidence for myocarditis) or Level 5 (not myocarditis) or have an alternative diagnosis such as myocardial infarction.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
mRNA COVID-19 vaccine associated myocarditis
Participants who had developed myocarditis within 42 days of getting a mRNA COVID-19 vaccine |
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives |
|
mRNA COVID-19 vaccine associated pericarditis
Participants who had developed pericarditis within 42 days of getting a mRNA COVID-19 vaccine |
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives |
|
COVID-19 infection associated myocarditis
Participants who had developed myocarditis within 42 days of being infected with the SARS-COV-2 virus |
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives |
|
COVID-19 infection associated pericarditis
Participants who had developed pericarditis within 42 days of being infected with the SARS-COV-2 virus |
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives |
|
Alternative etiology myocarditis
Any participants with myocarditis that is not associated with the mRNA COVID-19 vaccine or SARS-COV-2 viral infection |
Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Composite Major Adverse Cardiac Event (MACE) at 30 days post vaccination (preferred by cardiovascular community) and at 42 days post vaccination (preferred by vaccine monitoring investigators)
Tijdsspanne: From date of vaccination and up to 3 years
|
Including any of:
|
From date of vaccination and up to 3 years
|
|
Recovery of cardiac function in patients with previously documented abnormal cardiac function
Tijdsspanne: Through study completion, an average of 3 years
|
Patients with Left Ventricular Ejection Fraction (LVEF)<55% during anytime at baseline, with LVEF increase by 5% from worst baseline measurement |
Through study completion, an average of 3 years
|
|
Quality of life using validated instruments at baseline, 3 months, 12 months, and annually
Tijdsspanne: Through study completion, an average of 3 years
|
Quality of life: EQ-5D-5L questionnaire for adults or EQ-5D-Y questionnaire for children. |
Through study completion, an average of 3 years
|
|
Depression and anxiety using validated instruments at baseline, 3 months, 12 months, and annually
Tijdsspanne: Through study completion, an average of 3 years
|
Depression and anxiety data: PHQ-9 and GAD-7. |
Through study completion, an average of 3 years
|
|
Physical activity using validated instruments at baseline, 3 months, 12 months, and annually
Tijdsspanne: Through study completion, an average of 3 years
|
Physical activity: International Activity Questionnaire. |
Through study completion, an average of 3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Individuele componenten van het primaire samengestelde eindpunt 30 dagen en 42 dagen na mRNA-COVID-19-vaccinatie?
Tijdsspanne: Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
|
Aantal atriale aritmieën na mRNA-COVID-19-vaccinatie?
Tijdsspanne: Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
|
Percentage sterfte door alle oorzaken en cardiovasculaire sterfte na mRNA-COVID-19-vaccinatie?
Tijdsspanne: Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
|
Percentage ziekenhuisopnames, ongeacht de oorzaak en cardiovasculair, na mRNA-COVID-19-vaccinatie?
Tijdsspanne: Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
|
Herhalingspercentage van myocarditis/pericarditis na mRNA-COVID-19-vaccinatie?
Tijdsspanne: Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
|
Aantal constrictieve pericarditis na mRNA-COVID-19-vaccinatie?
Tijdsspanne: Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
Vanaf de datum van vaccinatie gedurende maximaal drie jaar
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Nathaniel Hawkins, MD, Vancouver General Hospital
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hart-en vaatziekten
- Hartziekten
- Cardiomyopathieën
- Myocarditis
- Pericarditis
- Diagnostische technieken en procedures
- Diagnose
- Milieu en volksgezondheid
- Fysieke fenomeen
- Tomografie
- Diagnostische beeldvorming
- Omgeving
- Ecologische en milieu -fenomenen
- Biologische fenomenen
- Geologische fenomeen
- Magnetische resonantie beeldvorming
- Grotten
Andere studie-ID-nummers
- MYCOVACC
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .